vaccine-induced immune thrombotic thrombocytopenia
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical condition
|
| gptkbp:abbreviation |
VITT
|
| gptkbp:causedBy |
gptkb:AstraZeneca_COVID-19_vaccine
gptkb:Johnson_&_Johnson_COVID-19_vaccine vaccine adenoviral vector vaccine |
| gptkbp:complication |
pulmonary embolism
deep vein thrombosis cerebral venous sinus thrombosis |
| gptkbp:firstReported |
2021
|
| gptkbp:hasMechanism |
autoimmune response
antibodies against platelet factor 4 |
| https://www.w3.org/2000/01/rdf-schema#label |
vaccine-induced immune thrombotic thrombocytopenia
|
| gptkbp:mortalityRate |
up to 20%
|
| gptkbp:onset |
5 to 30 days after vaccination
|
| gptkbp:riskFactor |
female sex
younger age |
| gptkbp:similarTo |
gptkb:heparin-induced_thrombocytopenia
|
| gptkbp:symptom |
thrombosis
thrombocytopenia blood clots low platelet count |
| gptkbp:treatment |
corticosteroids
intravenous immunoglobulin non-heparin anticoagulants |
| gptkbp:bfsParent |
gptkb:Cerebral_Venous_Thrombosis
|
| gptkbp:bfsLayer |
6
|